You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Small Molecule Inhibitor Therapeutic Target for Alzheimer's Disease.

    SBC: abSynapTex, LLC            Topic: NIA

    Project SummaryThe objective of our proposed research is to develop a water soluble molecule that can reduce the levels of amyloid betaAand Drpand prevent abnormal interactions between Aand Drpin Alzheimers diseaseADaffected neuronsOur previous AD studies foundincreased production and accumulation of Aand increased expression of Drpandan abnormal interaction between Aand Drpin AD neurons that was ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development and non-clinical GLP testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors.

    SBC: KIROMIC BIOPHARMA INC            Topic: NHLBI

    AtheroSclerotic CardioVascular DiseaseASCVDis caused by inflammation within arteriesWhite blood cells enter the arterial wallsmacrophages become engorged with lipid cholesterol and summon other inflammatory cells to form plaques which ultimately rupture or occlude the arterykilling down stream tissuee gheart attackASCVD remains a major cause of morbidity and mortality of the elderlyCoronary artery ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIDDK

    ABSTRACTA staggeringof US adults are obeseSince obesity greatly dysregulates glucose homeostasisalmost all obese individuals suffer from TypediabetesT Dor prediabetesThese diseasesand accompanying comorbid chronic health complicationsare largely responsible for burgeoning US healthcare costsUnfortunatelylife style modification programstypically the first line treatment for obesity linked T Drarely ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Tetracycline Analogs for Alcohol Use Disorder Treatment

    SBC: South Plains Biotechnology, Inc            Topic: 350

    Project Summary Abstract Statement of the problemOnly three pharmacotherapeutic treatments for Alcohol Use DisorderAUDare FDA approved and none are widely usedandltof AUD patientsor show a strong effect to reduce riskyor dependence based drinking in the long termandltsee sustained decreased drinking outcomesUnfortunatelyapproximatelyof the population suffers from AUD and overof all medical morbidi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: BERTEC CORP            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A 3D Printed Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices

    SBC: N8 MEDICAL INC            Topic: NHLBI

    ABSTRACT Infection is a serious and potentially fatal complication of surgery to deliver cardiovascular implantable electronic devicesCIEDsi epacemakers and implantable cardioverter defibrillatorsUntreated device related infection is associated with mortality rates as high asCurrentlyonly one antibiotic impregnated mesh has been FDA approved for placement in surgical incisions to reduce infections ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. TAPS-ESP: Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform: Technologies to Increase Screening in Primary Care to Reduce Behavioral Health Disparities

    SBC: COG ANALYTICS, LLC            Topic: 102

    ABSTRACTTAPS ESP Language accessibility and cultural awareness are essential elements of quality healthcareLimited English ProficiencyLEPindividuals are less likely to self identify a need for behavioral health serviceswhich results in longer duration of untreated disordersAccurate identificationdiagnosisand treatment are entirely dependent on a linguistically accurate screening and assessmentespe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development and Production of Standardized Reference Diets for Zebrafish Research

    SBC: Meridian Biotech, LLC            Topic: 101

    The over arching goal of this Phase I SBIR proposal is to begin to optimize and implement standard reference diets for the ZebrafishDanio rerioan animal model of critical importance to the understanding of human health and development of vertebrate organismsA key problem in the industry is that standardized diets or feed management strategies have not been developed for Danio rerioThese diets are ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Peripheral FAAH inhibitor, URB937, as an opioid-sparing analgesic for chronic pain.

    SBC: ASPIREBIO CORP            Topic: 101

    PROJECT SUMMARY Opioid drugs are powerful analgesicsbut their side effect profile strongly limits their useIndeedtheir addictive properties have led to an epidemic of abuse in the US that accounts forof the global utilization of prescription opioid analgesics in the USwith a market of over $billion per yearPrevious studies have shown that the endocannabinoid neurotransmitteranandamidecontrols noci ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government